Clinical Trials Logo

Clinically Isolated Syndrome clinical trials

View clinical trials related to Clinically Isolated Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04599023 Terminated - Multiple Sclerosis Clinical Trials

Assessing the Feasibility of the MSPT Device in Routine Clinical Practice in the Swiss Healthcare System

MSPT
Start date: October 16, 2020
Phase:
Study type: Observational

The Multiple Sclerosis Functional Composite (MSFC), a reliable and well-validated instrument, was developed as a multidimensional quantitative measure of neurologic disability in MS. However, the traditional form of the MSFC has various limitations, including the need for MS patients to be assessed in a clinical setting by trained technicians, which requires additional human resources and time in a clinical routine practice setting. Furthermore, storage of MSFC data for longitudinal comparison is difficult and time consuming. The MS Performance Test (MSPT) software tool is designed to objectively quantify the major motor, visual and cognitive function data, and quality of life outcomes, associated with MS and related disorders. This is a single center observational study that will examine the use of the MSPT in a real world setting. Study enrollment will occur at one center in Switzerland.

NCT ID: NCT04291456 Terminated - Multiple Sclerosis Clinical Trials

Minocycline in MS: Confirmation of Benefit

MS
Start date: January 31, 2020
Phase: Phase 3
Study type: Interventional

This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm in diameter, and at least one of which is ovoid or periventricular or infra-tentorial. Treatment with minocycline until the endpoint is reached or to a maximum of 24 months or until the last-enrolled participant reaches their 12 month visit.

NCT ID: NCT01039103 Terminated - Clinical trials for Clinically Isolated Syndrome

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Start date: December 2009
Phase: Phase 2
Study type: Interventional

Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol. Main objective is to assess the occurrence of new gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment.

NCT ID: NCT00819897 Terminated - Clinical trials for Clinically Isolated Syndrome

Longitudinal Study in Clinically Isolated Syndrome (CIS) Patients Treated With Interferon Beta

QUALICIS
Start date: June 2008
Phase: N/A
Study type: Observational

The aim of this study is to evaluate the role of cognitive disorders and quality of life in patients with CIS, considered as high risk to develop an MS, treated with interferon Beta. This prospective observational study will include 120 patients, all treated and evaluated annually with neurological extensive examination, ophthalmologic screening (OCT, OF, VEP, VF), auto questionnaire about fatigue (musicol, ELIF), quality of life (SEP-59), and conventional MRI.

NCT ID: NCT00595920 Terminated - Clinical trials for Multiple Sclerosis, Relapsing-Remitting

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

OLTERMS
Start date: November 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further evaluate the safety and efficacy of Tovaxin in the treatment of relapsing forms of multiple sclerosis.